Aktienanalyse zu Celcuity Inc. (CELC)CELCCelcuity Inc.

Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Celcuity Inc is a good buy right now due to its recent FDA approval of the cancer treatment Revtorpyk, which has a significant market potential given that HR+/HER2 breast cancer accounts for approximately 70% of over two million diagnosed cases globally. The current price is $65.25, and analysts have set price targets ranging from $140 to $178, indicating substantial upside potential. The RSI is at 57.197, suggesting that the stock is neither overbought nor oversold, which is favorable for entry. However, the main risk is the company's negative earnings trend, with a reported EPS of -1.44, which reflects ongoing financial challenges that could impact future performance.

1 analysts cover CELC: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 106.50.